Venlafaxine ingestion is associated with rhabdomyolysis in adults: A case series

Journal of Toxicological Sciences

Volumn 32, Issue 1, 2007, Pages 97-101

  Wilson, A D ^a   Howell, C ^a   Waring, W Stephen ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Drug toxicity; Myopathy; Overdose; Rhabdomyolysis

Indexed keywords

ALCOHOL; CREATINE KINASE; VENLAFAXINE;

ADULT; ARTICLE; CORRELATION COEFFICIENT; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG OVERDOSE; FEMALE; HOSPITALIZATION; HUMAN; INGESTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUSCLE INJURY; MYOPATHY; OUTCOME ASSESSMENT; PREVALENCE; RHABDOMYOLYSIS; SEIZURE;

ADULT; CREATINE KINASE; CYCLOHEXANOLS; FEMALE; HUMANS; MALE; OVERDOSE; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; SEIZURES; SEROTONIN UPTAKE INHIBITORS;

EID: 33847342019     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.97     Document Type: Article

References (15)

1. Balit, C.R., Isbister, G.K., Hackett, L.P. and Whyte, I.M. (2003): Quetiapine poisoning: A case series. Ann. Emerg. Med., 42, 751-758.
2. Ciuna, A., Andretta, M., Corbari, L., Levi, D., Mirandola, M., Sorio, A. and Barbui, C. (2004): Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur. J. Clin. Pharmacol., 60, 629-634.
3. Fogelman, S.M., Schmider, J., Venkatakrishnan, K., von Moltke, L.L., Harmatz, J.S., Shader, R.I. and Greenblatt, D.J. (1999): O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology, 20, 480-490.
4. Gaddis, G.M. and Gaddis, M.L. (1990): Introduction to biostatistics: Part 5, Statistical inference techniques for hypothesis testing with nonparametric data. Ann. Emerg. Med., 19, 1054-1059.
5. Hanekamp, B.B., Zijlstra, J.G., Tulleken, J.E., Ligtenberg, J.J., van der Werf, T.S. and Hofstra, L.S. (2005): Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: A case report. Neth. J. Med., 63, 316-318.
6. Holliday, S.M. and Benfield, P. (1995): Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs, 49, 280-294.
7. Johnson, E.M., Whyte, E., Mulsant, B.H., Pollock, B.G., Weber, E., Begley, A.E. and Reynolds, C.F. (2006): Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry, 14, 796-802.
8. Kelly, C.A., Dhaun, N., Laing, W.J., Strachan, F.E., Good, A.M. and Bateman, D.N. (2004): Comparative toxicity of citalopram and the newer antidepressants after overdose. J. Toxicol. Clin. Toxicol., 42, 67-71.
9. Lu, T.C., Chu, P.L., Wu, C.S., Tsai, K.C. and Chen, W.J. (2006): Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder. J. Formos. Med. Assoc., 105, 90-93.
10. Oliver, J.J., Kelly, C., Jarvie, D., Denieul, S. and Bateman, D.N. (2002): Venlafaxine poisoning complicated by a late rise in creatine kinase: Two case reports. Hum. Exp. Toxicol., 21, 463-436.
11. Pascale, P., Oddo, M., Pacher, P., Augsburger, M. and Liaudet, L. (2005): Severe rhabdomyolysis following venlafaxine overdose. Ther. Drug. Monit., 27, 562-564.
12. Stahl, S.M., Grady, M.M., Moret, C. and Briley, M. (2005): SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS. Spectr., 10, 732-747.
13. Troy, S.M., Turner, M.B., Unruh, M., Parker, V.D. and Chiang, S.T. (1997): Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. J. Clin. Pharmacol., 37, 1073-1081.
14. Whyte, I.M., Dawson, A.H. and Buckley, N.A. (2003): Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM., 96, 369-374.
15. Wilhelm, K., Curtis, J., Birkett, V. and Kenney-Herbert, J. (1994): The clinical significance of serial creatine phosphokinase estimations in acute ward admissions. Aust. N. Z. J. Psychiatry., 28, 453-457.